PharmaCyte Biotech
PMCB
25 hedge funds and large institutions have $8.83M invested in PharmaCyte Biotech in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 6 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
31% more call options, than puts
Call options by funds: $207K | Put options by funds: $158K
1.78% more ownership
Funds ownership: 16.75% → 18.53% (+1.8%)
2% more capital invested
Capital invested by funds: $8.68M → $8.83M (+$151K)
4% less funds holding
Funds holding: 26 → 25 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Shay Capital
New York
|
+$627K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$195K |
| 3 |
FIA
FNY Investment Advisers
New York
|
+$131K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$128K |
| 5 |
EPM
Equitec Proprietary Markets
Chicago,
Illinois
|
+$112K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$484K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$35K |
| 3 |
JF
Jump Financial
Chicago,
Illinois
|
-$26K |
| 4 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$22.5K |
| 5 |
Morgan Stanley
New York
|
-$13.9K |
PMCB Hedge Fund Activity: Q1 2022 in Review
25 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in PharmaCyte Biotech (PMCB) for Q1 2022, worth a combined $8.83M — up 1.7% from $8.68M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of PMCB and 5 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 8 added.
The largest buyer was Shay Capital, adding an estimated $627K. The largest seller was Anson Funds Management, exiting entirely with an estimated $484K sold.
- 25 institutional investors held PharmaCyte Biotech (PMCB) as of Q1 2022, down from 26 in Q4 2021.
- Funds reported $8.83M of PharmaCyte Biotech stock for Q1 2022, up 1.7% quarter-over-quarter.
- 5 funds opened new PharmaCyte Biotech positions in Q1 2022 and 6 closed out, a net change of -1 holder.
- The largest PharmaCyte Biotech buyer in Q1 2022 was Shay Capital, an estimated $627K added.
- The largest PharmaCyte Biotech seller in Q1 2022 was Anson Funds Management, an estimated $484K sold.
Based on aggregated 13F filings for Q1 2022.